

# SACHS ASSOCIATES 5<sup>th</sup> ANNUAL IMMUNO-ONCOLOGY BD&L AND INVESTMENT FORUM

31<sup>st</sup> May 2019 | Waldorf Astoria Chicago Hotel | USA

**07:20** Registration & Coffee **To Connect to Wi-Fi:**  
NETWORK: Hilton Honors Meeting  
PASSWORD: Waldorf2019

**08:10** Welcome Speech

**08:20** "The Oncology Anti-Gravity Machine: Can It Keep Working?" by Roger Longman, Co-Founder & Chairman, Real Endpoints LLC

**08:40** **Industry Roundtable** **Room Sinclair Ballroom**  
*Co-Chaired by:*  
**Biren Amin**, Managing Director, **Jefferies Group LLC**  
**Jeffrey Bockman**, EVP, Oncology Practice Head, **Cello Health BioConsulting**, previously **Defined Health**  
*Panelists:*  
**Iain Dukes**, Venture Partner, **OrbiMed Advisors LLC**  
**John DeYoung**, VP, Oncology Business Development, **Pfizer, Inc.**  
**Rafael Labrador**, Marketing Director, Market Access Oncology, **AbbVie, Inc.**  
**Roger Longman**, Co-Founder & Chairman, **Real Endpoints LLC**  
**Sophie Kornowski**, Senior Partner, **Gurnet Point Capital**  
**Stephen Sands**, Vice Chairman of Investment Banking & Chairman of Global Healthcare Group, **Lazard Ltd.**

**09:25** **Pharma-Bio DealMaking Panel** **Room Sinclair Ballroom**  
*Co-Chaired by:*  
**Michael Margolis**, Co-Head of Healthcare Investment Banking, **Oppenheimer & Co. Inc.**  
**Peter Sandor**, VP, Oncology Therapeutic Area Head for Marketing Strategy, **Astellas Pharma, Inc.**  
*Panelists:*  
**Chris DeRespino**, Executive Director, Business Development, **Amgen, Inc.**  
**Chris Sheldon**, Head of Oncology Search & Evaluation, **AstraZeneca**  
**Corinne Venot**, Sr. Director Business Development, **BeiGene Ltd.**  
**Niels Emmerich**, VP, Global Head Search & Evaluation, **AbbVie, Inc.**

**10:10** Coffee Break

<b>PR Track A - Room Sinclair Ballroom</b> <i>Moderated by:</i> <b>Kumaraguru Raja,</b> <b>Brookline Capital Markets</b>	<b>PR Track B - Room Faulkner</b> <i>Moderated by:</i> <b>Emad Samad,</b> <b>WBB Securities LLC</b>	<b>PR Track C - Room Sinclair North</b> <i>Moderated by:</i> <b>Sven Rohmann,</b> <b>Suenos Advisors Est.</b>
---	--	--

<b>10:30</b>	BeiGene Ltd. [NASDAQ: BGNE]	<b>10:30</b>	OSE Immunotherapeutics [EPA: OSE]	<b>10:30</b>	Immunomic Therapeutics, Inc.
<b>10:50</b>	Faron Pharmaceuticals Ltd. [LON: FARN]	<b>10:50</b>	Genocea Biosciences, Inc. [NASDAQ: GNCA]	<b>10:50</b>	EXUMA Biotechnology SEZC
<b>11:10</b>	Genprex, Inc. [NASDAQ: GNPX]	<b>11:10</b>	Immunicum AB [STO: IMMU]	<b>11:10</b>	Kleo Pharmaceuticals, Inc.
<b>11:30</b>	NOXXON Pharma NV [EPA: ALNOX]	<b>11:30</b>	BioInvent International AB [STO: BINV]	<b>11:30</b>	Refuge Biotechnologies, Inc.
<b>11:50</b>	Celyad [EBR: CYAD]	<b>11:50</b>	Phio Pharmaceuticals Corp. [NASDAQ: PHIO]	<b>11:50</b>	Compass Therapeutics LLC
<b>12:10</b>	Anixa Biosciences, Inc. [NASDAQ: ANIX]	<b>12:10</b>	Marker Therapeutics, Inc. [NASDAQ: MRKR]	<b>12:10</b>	SciNote LLC
				<b>12:20</b>	Convergent R.N.R Ltd.
<b>12:30</b>	Oxford Biomedica Plc. [LON: OXB]			<b>12:30</b>	Rainier Therapeutics, Inc.

**12:50** Networking Lunch

13:40	<p><b>Revised Strategies for Advanced Therapeutics Panel</b>  <i>Co-Chaired by:</i>  <b>James Mulé</b>, Associate Center Director for Translational Research, <b>Moffitt Cancer Center Foundation</b>  <b>Paul Rennert</b>, President &amp; CSO, <b>Aleta Biotherapeutics</b></p> <p><i>Panelists:</i>  <b>Alexis Peyroles</b>, CEO, <b>OSE Immunotherapeutics</b>  <b>Carlos de Sousa</b>, CEO, <b>Immunicum AB</b>  <b>Girish Aakalu</b>, CBO, <b>Genocea Biosciences, Inc.</b>  <b>Jing Zhao</b>, CBO, <b>Refuge Biotechnologies, Inc.</b>  <b>Loïc Vincent</b>, Head, Oncology &amp; Immunology Research Partnerships &amp; Head, Oncology Cell Therapy, <b>Takeda Pharmaceutical Company</b>  <b>Thomas Schuetz</b>, Co-Founder &amp; CEO, <b>Compass Therapeutics LLC</b></p>	Room Sinclair Ballroom	<p>PR Track D - Room Faulkner  <i>Moderated by:</i>  <b>James Lee</b>,  <b>Cello Health BioConsulting</b>,  previously <b>Defined Health</b></p>
14:30	<p><b>Latest Advances in Cell &amp; Gene Therapies Panel</b>  <i>Co-Chaired by:</i>  <b>Axel Hoos</b>, SVP, Therapeutic Area Head of Oncology R&amp;D, <b>GlaxoSmithKline</b>  <b>Gregory Frost</b>, Managing Director, <b>F1BioVentures LLC</b></p> <p><i>Panelists:</i>  <b>Filippo Petti</b>, CEO, <b>Celyad</b>  <b>Helen Tayton-Martin</b>, CBO, <b>Adaptimmune</b>  <b>Jason Slingsby</b>, CBO, <b>Oxford BioMedica Plc.</b>  <b>Matthias Müllenbeck</b>, Director Global Business Development &amp; Licensing, Oncology, <b>Merck KGaA</b>  <b>Peter Hoang</b>, President &amp; CEO, <b>Marker Therapeutics, Inc.</b>  <b>Timothy Herpin</b>, CBO, <b>Caribou Biosciences, Inc.</b></p>	Room Sinclair Ballroom	<p>13:40 VCN Biosciences SL</p> <p>14:00 Immunicom, Inc.</p> <p>14:20 SIWA Therapeutics, Inc.</p> <p>14:40 Triumvira Immunologics, Inc.</p> <p>15:00 Sirnaomics, Inc.</p>
15:20	<b>Coffee Break</b>		
15:40	<p><b>China-US Partnering &amp; Investment Panel</b>  <i>Co-Chaired by:</i>  <b>Guillaume Vignon</b>, SVP, Business Development, <b>BeiGene Ltd.</b>  <b>Helen Chen</b>, Greater China Managing Partner &amp; Head of China Life Sciences, <b>L.E.K. Consulting</b></p> <p><i>Panelists:</i>  <b>Echo Hindle-Yang</b>, Founder &amp; CEO, <b>MSQ Ventures</b>  <b>Ji Li</b>, Venture Partner, <b>Lilly Asia Ventures</b>  <b>Mark Wiggins</b>, CBO, <b>Tracon Pharmaceuticals</b>  <b>May Wang</b>, SVP, Head of BD &amp; Strategic Alliances, <b>Hutchison China MediTech Ltd.</b>  <b>Yuwen Liu</b>, Founding Partner, <b>BOHE Angel Fund</b></p>	Room Sinclair Ballroom	
16:30	<p><b>Innovation Panel</b>  <i>Co-Chaired by:</i>  <b>Kuldeep Neote</b>, VP External Innovation, <b>Eli Lilly and Company</b>  <b>Prem Das</b>, Executive Advisor, BD &amp; Strategy, <b>X-Chem, Inc.</b></p> <p><i>Panelists:</i>  <b>Dave Greenwald</b>, VP, Business Development, <b>Deerfield Management</b>  <b>Hanne Mette Dyrлие Kristensen</b>, Special Advisor, Invest In Norway Life Science &amp; Health, <b>Innovation Norway</b>  <b>Michal Preminger</b>, Head of J&amp;J Innovation, East North America, <b>Johnson &amp; Johnson Innovation</b>  <b>Ryan Schoenfeld</b>, Senior Scientific Director, <b>The Mark Foundation for Cancer Research</b>  <b>Yogen Saunthararajah</b>, Prof. of Medicine, Co-Leader of the Developmental Therapeutics Program &amp; Staff Physician, <b>Cleveland Clinic</b></p>	Room Sinclair Ballroom	
17:15	<p><b>Investor Discussion</b>  <i>Co-Chaired by:</i>  <b>Boris Peaker</b>, Managing Director, Biotechnology Equity Research, <b>Cowen, Inc.</b>  <b>Brad Loncar</b>, CEO, <b>Loncar Investment LLC</b></p> <p><i>Panelists:</i>  <b>Bibhash Mukhopadhyay</b>, Principal, <b>New Enterprise Associates (NEA)</b>  <b>Carolyn Ng</b>, Managing Director, <b>Vertex Ventures HC</b>  <b>Jason Wang</b>, Director of Business Development, <b>Fortress Biotech</b>  <b>Shinichiro Fuse</b>, Managing Director, <b>MPM Capital, Inc.</b>  <b>Thilo Schroeder</b>, Partner, <b>Nextech Invest Ltd.</b></p>	Room Sinclair Ballroom	
18:00	<b>Networking Reception</b>		
19:00	<b>End of the 5<sup>th</sup> IOBDLI Forum</b>		

**SILVER SPONSOR:**



**SUPPORTED BY:**

